BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 32365913)

  • 1. Mutation-Associated Phenotypic Heterogeneity in Novel and Canonical PIK3CA Helical and Kinase Domain Mutants.
    Ghodsinia AA; Lego JMT; Garcia RL
    Cells; 2020 Apr; 9(5):. PubMed ID: 32365913
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Functional role of SGK3 in PI3K/Pten driven liver tumor development.
    Cao H; Xu Z; Wang J; Cigliano A; Pilo MG; Ribback S; Zhang S; Qiao Y; Che L; Pascale RM; Calvisi DF; Chen X
    BMC Cancer; 2019 Apr; 19(1):343. PubMed ID: 30975125
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PIK3CA mutation spectrum in urothelial carcinoma reflects cell context-dependent signaling and phenotypic outputs.
    Ross RL; Askham JM; Knowles MA
    Oncogene; 2013 Feb; 32(6):768-76. PubMed ID: 22430209
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The E545K mutation of PIK3CA promotes gallbladder carcinoma progression through enhanced binding to EGFR.
    Zhao S; Cao Y; Liu SB; Wang XA; Bao RF; Shu YJ; Hu YP; Zhang YJ; Jiang L; Zhang F; Liang HB; Li HF; Ma Q; Xu Y; Wang Z; Zhang YC; Chen L; Zhou J; Liu YB
    J Exp Clin Cancer Res; 2016 Jun; 35(1):97. PubMed ID: 27317099
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phosphoproteomic screen demonstrates differential dependence on HER3 for MAP kinase pathway activation by distinct PIK3CA mutations.
    Blair BG; Wu X; Zahari MS; Mohseni M; Cidado J; Wong HY; Beaver JA; Cochran RL; Zabransky DJ; Croessmann S; Chu D; Toro PV; Cravero K; Pandey A; Park BH
    Proteomics; 2015 Jan; 15(2-3):318-26. PubMed ID: 25367220
    [TBL] [Abstract][Full Text] [Related]  

  • 6. AKT1 E17K in Colorectal Carcinoma Is Associated with BRAF V600E but Not MSI-H Status: A Clinicopathologic Comparison to PIK3CA Helical and Kinase Domain Mutants.
    Hechtman JF; Sadowska J; Huse JT; Borsu L; Yaeger R; Shia J; Vakiani E; Ladanyi M; Arcila ME
    Mol Cancer Res; 2015 Jun; 13(6):1003-8. PubMed ID: 25714871
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PIK3CA hotspot mutations differentially impact responses to MET targeting in MET-driven and non-driven preclinical cancer models.
    Nisa L; Häfliger P; Poliaková M; Giger R; Francica P; Aebersold DM; Charles RP; Zimmer Y; Medová M
    Mol Cancer; 2017 May; 16(1):93. PubMed ID: 28532501
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection of PIK3CA Mutations in Plasma DNA of Colorectal Cancer Patients by an Ultra-Sensitive PNA-Mediated PCR.
    Zeng Q; Xie L; Zhou N; Liu M; Song X
    Mol Diagn Ther; 2017 Aug; 21(4):443-451. PubMed ID: 28247181
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibitors of STAT3, β-catenin, and IGF-1R sensitize mouse PIK3CA-mutant breast cancer to PI3K inhibitors.
    Merino VF; Cho S; Liang X; Park S; Jin K; Chen Q; Pan D; Zahnow CA; Rein AR; Sukumar S
    Mol Oncol; 2017 May; 11(5):552-566. PubMed ID: 28296140
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Highly sensitive detection of the PIK3CA (H1047R) mutation in colorectal cancer using a novel PCR-RFLP method.
    Li WM; Hu TT; Zhou LL; Feng YM; Wang YY; Fang J
    BMC Cancer; 2016 Jul; 16():454. PubMed ID: 27405731
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection of PIK3CA gene mutations with HRM analysis and association with IGFBP-5 expression levels in breast cancer.
    Dirican E; Kaya Z; Gullu G; Peker I; Ozmen T; Gulluoglu BM; Kaya H; Ozer A; Akkiprik M
    Asian Pac J Cancer Prev; 2014; 15(21):9327-33. PubMed ID: 25422220
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-Redundant and Overlapping Oncogenic Readouts of Non-Canonical and Novel Colorectal Cancer KRAS and NRAS Mutants.
    Alcantara KMM; Malapit JRP; Yu RTD; Garrido JAMG; Rigor JPT; Angeles AKJ; Cutiongco-de la Paz EM; Garcia RL
    Cells; 2019 Dec; 8(12):. PubMed ID: 31816869
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PIK3CA mutation affects the proliferation of colorectal cancer cells through the PI3K-MEK/PDK1-GPT2 pathway.
    Chen W; Dai G; Qian Y; Wen L; He X; Liu H; Gao Y; Tang X; Dong B
    Oncol Rep; 2022 Jan; 47(1):. PubMed ID: 34751411
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Functional analysis of PIK3CA gene mutations in human colorectal cancer.
    Ikenoue T; Kanai F; Hikiba Y; Obata T; Tanaka Y; Imamura J; Ohta M; Jazag A; Guleng B; Tateishi K; Asaoka Y; Matsumura M; Kawabe T; Omata M
    Cancer Res; 2005 Jun; 65(11):4562-7. PubMed ID: 15930273
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PI3K oncogenic mutations mediate resistance to afatinib in HER2/neu overexpressing gynecological cancers.
    Bonazzoli E; Cocco E; Lopez S; Bellone S; Zammataro L; Bianchi A; Manzano A; Yadav G; Manara P; Perrone E; Haines K; Espinal M; Dugan K; Menderes G; Altwerger G; Han C; Zeybek B; Litkouhi B; Ratner E; Silasi DA; Huang GS; Azodi M; Schwartz PE; Santin AD
    Gynecol Oncol; 2019 Apr; 153(1):158-164. PubMed ID: 30630630
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gain of interaction with IRS1 by p110α-helical domain mutants is crucial for their oncogenic functions.
    Hao Y; Wang C; Cao B; Hirsch BM; Song J; Markowitz SD; Ewing RM; Sedwick D; Liu L; Zheng W; Wang Z
    Cancer Cell; 2013 May; 23(5):583-93. PubMed ID: 23643389
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phosphatidyl inositol-3 kinase (PIK3CA) E545K mutation confers cisplatin resistance and a migratory phenotype in cervical cancer cells.
    Arjumand W; Merry CD; Wang C; Saba E; McIntyre JB; Fang S; Kornaga E; Ghatage P; Doll CM; Lees-Miller SP
    Oncotarget; 2016 Dec; 7(50):82424-82439. PubMed ID: 27489350
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of Lipid Alterations by Oncogenic
    Jung JH; Yang DQ; Song H; Wang X; Wu X; Kim KP; Pandey A; Byeon SK
    OMICS; 2023 Jul; 27(7):327-335. PubMed ID: 37463468
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential enhancement of breast cancer cell motility and metastasis by helical and kinase domain mutations of class IA phosphoinositide 3-kinase.
    Pang H; Flinn R; Patsialou A; Wyckoff J; Roussos ET; Wu H; Pozzuto M; Goswami S; Condeelis JS; Bresnick AR; Segall JE; Backer JM
    Cancer Res; 2009 Dec; 69(23):8868-76. PubMed ID: 19903845
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activating PIK3CA Mutations Induce an Epidermal Growth Factor Receptor (EGFR)/Extracellular Signal-regulated Kinase (ERK) Paracrine Signaling Axis in Basal-like Breast Cancer.
    Young CD; Zimmerman LJ; Hoshino D; Formisano L; Hanker AB; Gatza ML; Morrison MM; Moore PD; Whitwell CA; Dave B; Stricker T; Bhola NE; Silva GO; Patel P; Brantley-Sieders DM; Levin M; Horiates M; Palma NA; Wang K; Stephens PJ; Perou CM; Weaver AM; O'Shaughnessy JA; Chang JC; Park BH; Liebler DC; Cook RS; Arteaga CL
    Mol Cell Proteomics; 2015 Jul; 14(7):1959-76. PubMed ID: 25953087
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.